MX353143B - Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. - Google Patents
Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.Info
- Publication number
- MX353143B MX353143B MX2013009662A MX2013009662A MX353143B MX 353143 B MX353143 B MX 353143B MX 2013009662 A MX2013009662 A MX 2013009662A MX 2013009662 A MX2013009662 A MX 2013009662A MX 353143 B MX353143 B MX 353143B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- biological markers
- cell antagonists
- predicting response
- patients
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
Abstract
La presente invención se refiere a marcadores biológicos que pronostican la respuesta de pacientes antagonistas de células B. También se proporcionan métodos para utilizar estos marcadores biológicos. Además, se proporcionan métodos para identificar pacientes que sufren de una enfermedad autoinmune, e.g., artritis reumatoide, que probablemente no responderán a antagonistas de células-B, al igual que métodos para tratar a dichos pacientes. También se proporcionan métodos para seleccionar agentes terapéuticos para tratar a dichos pacientes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161447518P | 2011-02-28 | 2011-02-28 | |
US201161527525P | 2011-08-25 | 2011-08-25 | |
PCT/US2012/026774 WO2012118750A2 (en) | 2011-02-28 | 2012-02-27 | Biological markers and methods for predicting response to b-cell antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013009662A MX2013009662A (es) | 2014-02-11 |
MX353143B true MX353143B (es) | 2017-12-20 |
Family
ID=46758440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013009662A MX353143B (es) | 2011-02-28 | 2012-02-27 | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20140154247A1 (es) |
EP (1) | EP2680884B1 (es) |
JP (1) | JP6271254B2 (es) |
KR (1) | KR20140022815A (es) |
CN (1) | CN103502472B (es) |
BR (1) | BR112013021725A2 (es) |
CA (1) | CA2827859A1 (es) |
MX (1) | MX353143B (es) |
RU (1) | RU2013140975A (es) |
WO (1) | WO2012118750A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2380911T3 (pl) | 2003-11-05 | 2018-10-31 | Roche Glycart Ag | Cząsteczki wiążące antygen o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej |
JP5254807B2 (ja) | 2007-01-23 | 2013-08-07 | 国立大学法人信州大学 | 慢性拒絶反応抑制剤 |
CN102256623A (zh) | 2008-06-05 | 2011-11-23 | 独立行政法人国立癌症研究中心 | 神经浸润抑制剂 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
KR20140022815A (ko) | 2011-02-28 | 2014-02-25 | 제넨테크, 인크. | B-세포 길항제에 대한 반응을 예측하기 위한 생물학적 마커 및 방법 |
WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
CA2880117C (en) | 2012-07-27 | 2021-04-06 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
EP2951586A1 (en) * | 2013-01-31 | 2015-12-09 | The University of Birmingham | Biomarkers of autoimmune and/or chronic diseases associated with joint inflammation |
EP3009518B1 (en) * | 2013-06-11 | 2020-08-12 | National Center of Neurology and Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
WO2015066640A1 (en) * | 2013-11-01 | 2015-05-07 | The Research Institute At Nationwide Children's Hospital | Kit and method for identifying individual responsiveness to steroid therapy of nephrotic syndrome |
EP3114233B1 (en) * | 2014-03-03 | 2018-04-04 | Assistance Publique Hôpitaux de Paris | A method for predicting the responsiveness a patient to a treatment with an anti-cd20 antibody |
GB201412736D0 (en) | 2014-07-17 | 2014-09-03 | Univ London Queen Mary | Method |
KR20180095740A (ko) | 2015-02-27 | 2018-08-27 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
PL3299810T3 (pl) | 2015-05-19 | 2021-12-13 | National Center Of Neurology And Psychiatry | Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm) |
WO2017055320A1 (en) * | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample |
WO2017055326A1 (en) * | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
WO2017055319A1 (en) * | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of b cells in a tissue sample |
WO2017055325A1 (en) * | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of nk cells in a tissue sample |
WO2018013917A1 (en) | 2016-07-15 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
WO2018017569A1 (en) * | 2016-07-19 | 2018-01-25 | Arete Discoveries, Inc. | Biomarkers for detection and treatment of mast cell activity-associated disorders |
TW201836642A (zh) * | 2017-03-24 | 2018-10-16 | 美商建南德克公司 | 治療自體免疫及發炎疾病的方法 |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
US10474681B1 (en) * | 2017-09-26 | 2019-11-12 | Microsoft Technology Licensing, Llc | Filtering mapped datasets |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
EP3710032A4 (en) * | 2017-11-15 | 2021-12-15 | The Translational Genomics Research Institute | SUBSTITUTION BIOMARKERS TESTING AND STANDARD BLOOD CHEMISTRY TEST METHODS |
EP3737362A1 (en) | 2018-01-12 | 2020-11-18 | Kdac Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
EP3728638A1 (en) * | 2018-01-24 | 2020-10-28 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra) |
WO2019241158A1 (en) * | 2018-06-11 | 2019-12-19 | Univerity Of Washington | Compositions and methods for treating inflammatory diseases |
WO2020014599A1 (en) * | 2018-07-13 | 2020-01-16 | Teqla Therapeutics, Inc. | Use of bcl6 inhibitors for treating autoimmune diseases |
CA3138086A1 (en) | 2019-05-20 | 2020-11-26 | Massachusetts Institute Of Technology | Boronic ester prodrugs and uses thereof |
WO2021207508A1 (en) * | 2020-04-09 | 2021-10-14 | Myriad Genetics, Inc. | Methods of predicting disease progression in rheumatoid arthritis |
CN112669929B (zh) * | 2020-12-30 | 2021-08-03 | 深圳大学 | 克罗恩病英夫利昔单抗药效预测方法及终端设备 |
GB202116748D0 (en) * | 2021-11-19 | 2022-01-05 | Univ London Queen Mary | Method for treating rheumatoid arthritis |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP3904238B2 (ja) | 1996-03-20 | 2007-04-11 | イムノメディクス, インコーポレイテッド | グリコシル化されたヒト化b細胞特異的抗体 |
BR9612752A (pt) | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
EA200000311A1 (ru) | 1997-09-12 | 2000-10-30 | Апотек Р Энд Д Са | Новый белок иммунной системы - кау |
WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
ES2329254T3 (es) | 1999-01-07 | 2009-11-24 | Zymogenetics, Inc. | Usos terapeuticos de receptores solubles de br43x2. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
WO2000074718A1 (en) | 1999-06-09 | 2000-12-14 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
HU230583B1 (hu) | 1999-08-17 | 2017-02-28 | Biogen Idec Ma Inc. | BAFF-receptor (BCMA) alkalmazásai immunszabályozó szerként |
DE10041402A1 (de) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
JP2003533218A (ja) | 2000-05-12 | 2003-11-11 | アムジエン・インコーポレーテツド | April/g70、bcma、blys/agp−3及びtaciに関する物質の組成物及び使用方法 |
PT2275449T (pt) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
CA2418006A1 (en) | 2000-08-18 | 2002-02-28 | Dyax Corp. | Binding polypeptides for b lymphocyte stimulator protein (blys) |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
EP1407017B1 (en) | 2000-11-07 | 2009-06-03 | ZymoGenetics, Inc. | Human tumor necrosis factor receptor |
CA2438682A1 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
NZ529267A (en) | 2001-05-11 | 2006-05-26 | Amgen Inc | Peptides and related molecules that bind to tall-1 |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
WO2003014294A2 (en) | 2001-08-03 | 2003-02-20 | Genentech, Inc. | Tacis and br3 polypeptides and uses thereof |
AU2002330074A1 (en) | 2001-09-21 | 2003-04-01 | Amgen Inc. | Tall-1 receptor molecules and uses thereof |
US7825089B2 (en) | 2001-10-24 | 2010-11-02 | National Jewish Health | Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto |
RU2004127458A (ru) | 2002-02-14 | 2005-10-27 | Иммуномедикс, Инк. (Us) | Анти-cd20 антитела, их гибридные белки и способы их использования |
DE60334364D1 (de) | 2002-02-21 | 2010-11-11 | Univ California | Behandlungsverfahren unter verwendung von anti-cd22-antikörpern |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
WO2004009479A1 (en) | 2002-07-18 | 2004-01-29 | Fabio Perini S.P.A. | Storage unit for elongated products |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
ATE540978T1 (de) | 2002-10-17 | 2012-01-15 | Genmab As | Humane monoklonale antikörper gegen cd20 |
ES2633311T3 (es) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
EP1629001A2 (en) | 2003-06-05 | 2006-03-01 | Genentech, Inc. | Blys antagonists and uses thereof |
DK2272868T3 (en) * | 2003-06-05 | 2015-06-15 | Genentech Inc | Combination therapy for B-cell diseases |
US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
MXPA06014067A (es) | 2004-06-04 | 2007-02-15 | Genentech Inc | Metodo para tratar lupus. |
RU2411956C2 (ru) | 2004-10-05 | 2011-02-20 | Дженентек, Инк. | Способ лечения васкулита |
AU2006259583A1 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
ZA200801354B (en) | 2005-08-09 | 2009-08-26 | Ares Trading Sa | Methods for treating B-cell malignancies using TACI-lg fusion molecule |
WO2007038501A2 (en) | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
CN101405685A (zh) | 2006-03-15 | 2009-04-08 | 皇家飞利浦电子股份有限公司 | 具有滚动检测的遥控指向技术 |
EP1857559A1 (en) | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
WO2008156494A1 (en) | 2006-11-03 | 2008-12-24 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders |
CA2668955A1 (en) | 2006-11-09 | 2008-05-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents |
EP2132343B1 (en) | 2007-03-01 | 2012-08-29 | Université Catholique de Louvain | Method for the determination and the classification of rheumatic conditions |
TW200902725A (en) * | 2007-04-02 | 2009-01-16 | Genentech Inc | Biological markers predictive of rheumatoid arthritis response to B-cell antagonists |
WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
BRPI0812461A2 (pt) | 2007-06-08 | 2017-06-13 | Biogen Idec Inc | método de prever a resposta de um indivíduo a uma terapia, método de tratamento de um distúrbio imunológico, composição e kit |
US20100285007A1 (en) * | 2007-09-14 | 2010-11-11 | The Uab Research Foundation | Differential diagnosis of b-cell chronic lymphocytic leukemia |
JP5730576B2 (ja) * | 2007-11-07 | 2015-06-10 | ジェネンテック, インコーポレイテッド | 抗cd40抗体による治療に対するb細胞リンパ腫の応答性を評価するための方法及び組成物 |
ES2351456B1 (es) * | 2009-06-24 | 2011-11-28 | Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron | Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b |
KR20120104517A (ko) * | 2009-09-03 | 2012-09-21 | 제넨테크, 인크. | 류마티스 관절염의 치료, 진단 및 모니터링 방법 |
KR20140022815A (ko) | 2011-02-28 | 2014-02-25 | 제넨테크, 인크. | B-세포 길항제에 대한 반응을 예측하기 위한 생물학적 마커 및 방법 |
-
2012
- 2012-02-27 KR KR1020137025286A patent/KR20140022815A/ko not_active Application Discontinuation
- 2012-02-27 MX MX2013009662A patent/MX353143B/es active IP Right Grant
- 2012-02-27 CN CN201280019766.3A patent/CN103502472B/zh not_active Expired - Fee Related
- 2012-02-27 BR BR112013021725A patent/BR112013021725A2/pt not_active IP Right Cessation
- 2012-02-27 RU RU2013140975/10A patent/RU2013140975A/ru not_active Application Discontinuation
- 2012-02-27 JP JP2013556776A patent/JP6271254B2/ja not_active Expired - Fee Related
- 2012-02-27 CA CA2827859A patent/CA2827859A1/en not_active Abandoned
- 2012-02-27 EP EP12752355.3A patent/EP2680884B1/en not_active Not-in-force
- 2012-02-27 WO PCT/US2012/026774 patent/WO2012118750A2/en active Application Filing
-
2013
- 2013-08-23 US US13/974,817 patent/US20140154247A1/en not_active Abandoned
-
2016
- 2016-02-09 US US15/019,615 patent/US9982302B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2014512806A (ja) | 2014-05-29 |
JP6271254B2 (ja) | 2018-01-31 |
CA2827859A1 (en) | 2012-09-07 |
RU2013140975A (ru) | 2015-04-10 |
CN103502472A (zh) | 2014-01-08 |
WO2012118750A2 (en) | 2012-09-07 |
EP2680884A4 (en) | 2015-07-08 |
US9982302B2 (en) | 2018-05-29 |
US20140154247A1 (en) | 2014-06-05 |
US20160265056A1 (en) | 2016-09-15 |
BR112013021725A2 (pt) | 2016-11-01 |
CN103502472B (zh) | 2017-06-06 |
EP2680884A2 (en) | 2014-01-08 |
EP2680884B1 (en) | 2018-01-17 |
WO2012118750A3 (en) | 2013-11-14 |
KR20140022815A (ko) | 2014-02-25 |
MX2013009662A (es) | 2014-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX353143B (es) | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. | |
MX2012002766A (es) | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. | |
MX355543B (es) | Macrociclos peptidomiméticos. | |
WO2011154139A3 (en) | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment | |
MX2014006158A (es) | Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa. | |
EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
JO3766B1 (ar) | منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني | |
PH12014501844B1 (en) | Peptidomimetic macrocycles | |
MX2014000518A (es) | Inhibidores de la tirosina quinasa de bruton. | |
MY176903A (en) | Compounds and methods for kinase modulation, and indications therefor | |
MX356107B (es) | Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias. | |
MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
MX351428B (es) | Métodos in vitro para correlacionar el nivel de sr2 solubre y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular. | |
MX342810B (es) | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. | |
MX2012001716A (es) | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. | |
MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
MY201478A (en) | Antibodies and assays for detection of folate receptor 1 | |
MX2013000675A (es) | Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer. | |
TW200637574A (en) | Treatment method | |
MY167920A (en) | HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF | |
TN2014000513A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
MX360774B (es) | Antagonistas de progesterona. | |
JO3715B1 (ar) | منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني | |
WO2013160315A3 (en) | Genetic predictors of response to treatment with crhr1 antagonists | |
NZ626242A (en) | Anti-asic1 antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |